Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Helsinn And AB Science Persevere In EU Despite CHMP Setback

Executive Summary

Helsinn and AB Science plan to conduct additional studies with their products the CHMP turned down this month, in an effort to secure eventual EU approval in the rejected indications. A third company, XBiotech, hasn’t ruled out similar action. New MAAs would be required.


Related Content

CHMP Readies ‘Outstanding Issues’ Lists For Products Nearing EU Review End
XBiotech Says CHMP ‘No’ Was A Surprise, Despite The Signs
New Treatments For Psoriasis, Ovarian Cancer And MS Seeking CHMP Thumbs Up This Week
Three CHMP Negative Opinions ‒ But Who Got A Boon?
AB Science Asks For Re-examination After EMA Rejects Masitinib For Mastocytosis
Four companies request CHMP second opinion
AB Science plummets on second CHMP rejection for canine anticancer


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts